Detail of the clinical trial

Title of the trial A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses
EudraCT number 2014-001617-12
Protocol number AP24534-14-203
Sponsor ARIAD Pharmaceuticals, Inc., 26 Landsdowne Street, Cambridge, MA 02139, United States of America
Indications Hemato-oncology
Diagnosis Chronic Myeloid Leukemia
Population in clinical trial Adults (18-65 years)
Elderly ( > 65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2016
Date of approval by Institute (SÚKL) 17.1.2017
Date of approval by EC
Date of initiation CT in ČR
Date of ending CT in ČR
Notice
Sites Ústav hematologie a krevní transfúze, U Nemocnice 2094/1,Praha 2,12820
Fakultní nemocnice Olomouc, I.P.Pavlova 6,Olomouc,77520

‹‹ Back to list